Neonode Reports Quarter Ended March 31, 2025 Financial Results — Neutral
NEON PRNewsWire — May 14, 2025STOCKHOLM , May 14, 2025 /PRNewswire/ -- Neonode Inc. (NASDAQ: NEON) ("Neonode" or the "Company") today reported financial results for the three months ended March 31, 2025. FINANCIAL SUMMARY FOR THE QUARTER ENDED MARCH 31, 2025: Revenues from continuing operations of $0.5 million, a decrease of 37.0% compared to the same period in the prior year.

The Gap: Turnaround Progress Matters More Than Industry Turmoil — Positive
GAP Seeking Alpha — May 14, 2025The Gap, Inc. has continued to show turnaround progress. The Old Navy and Gap brands are showing increased relevance, and Gap's cost focus is expanding margins significantly. The upcoming Q1 report should show similar underlying trends. On the other hand, consumer weakness amid tariff uncertainty pressures the industry outlook. Based on turnaround progress, GAP stock remains undervalued. I estimate 42% upside to $36.1.

Super Micro's stock keeps surging. Here's what might come next. — Positive
SMCI Market Watch — May 14, 2025Saudi Arabia's plan to invest $20 billion in U.S. artificial-intelligence data centers and energy infrastructure creates big opportunities for AI stocks.

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June — Neutral
EDIT GlobeNewsWire — May 14, 2025Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that new data from a study in non-human primates (NHPs) has been accepted for a poster presentation at the European Hematology Association (EHA) 2025 Congress being held June 12-15, 2025, in Milan, Italy.

TELUS Health acquires Workplace Options, top provider of wellbeing services to Fortune 500 companies — Neutral
TU PRNewsWire — May 14, 2025TELUS Health combines digital-first innovation with Workplace Options' Employee and Family Assistance Program to transform employee wellbeing solutions GTCR to invest US$200 million as part of the acquisition, bringing strategic healthcare industry expertise to accelerate TELUS Health's global growth and innovation VANCOUVER, BC and TORONTO , May 14, 2025 /PRNewswire/ - TELUS Corporation ("TELUS") (TSX: T) (NYSE: TU) today announced a strategic partnership with GTCR, a leading private equity investor with extensive expertise across the healthcare landscape, supporting TELUS Health's recently announced acquisition of Workplace Options. Last week, TELUS Health announced the acquisition of Workplace Options for cash of approximately …

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting — Neutral
KPTI PRNewsWire — May 14, 2025NEWTON, Mass. , May 14, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy.

VAALCO Energy to Execute Drilling Plans & FPSO Refurbishment in Africa — Positive
EGY Zacks Investment Research — May 14, 2025EGY's plans in Cote d'Ivoire involve the refurbishment of the FPSO at the Baobab field in Block CI-40. In Gabon, EGY is gearing up for the 2025/2026 drilling program.

Best Growth Stocks to Buy for May 14th — Positive
EWCZ STRT SWX Zacks Investment Research — May 14, 2025STRT, EWCZ and SWX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 14, 2025.

The US DoC has scrapped the AI Diffusion export controls, removing a major regulatory overhang and reigniting Nvidia's global Sovereign AI ambitions. Nvidia's new multi-billion dollar deals in the Middle East, especially with Saudi Arabia, could add an estimated $63B in high-margin revenue. Nvidia's ex-USA business is rapidly accelerating, and these catalysts are not yet reflected in consensus analyst forecasts or current valuation multiples.

Kornit Digital (KRNT) Q1 Earnings and Revenues Top Estimates — Positive
KRNT Zacks Investment Research — May 14, 2025Kornit Digital (KRNT) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.11 per share a year ago.

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma — Neutral
NRIX GlobeNewsWire — May 14, 2025SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company's ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia will be presented at two major upcoming scientific conferences.

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress — Neutral
BEAM GlobeNewsWire — May 14, 2025Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) — Neutral
SNDX GlobeNewsWire — May 14, 2025– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r –

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 — Neutral
TERN GlobeNewsWire — May 14, 2025Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress — Neutral
AUTL GlobeNewsWire — May 14, 2025LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 12-15, 2025, Milan, Italy. Autolus will have two oral and one poster presentation, which includes updated follow up from the FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL).

Berman Tabacco Notifies Investors Lead Plaintiff Deadline in Securities Class Action Against Compass Diversified Holdings (CODI) — Neutral
CODI GlobeNewsWire — May 14, 2025BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Berman Tabacco announces that a securities class action alleging violations of the Securities Exchange Act of 1934 has been filed against Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI), and others, on behalf of persons or entities who purchased or otherwise acquired publicly traded Compass securities between May 1, 2024, and May 7, 2025, inclusive (the “Class Period”). The case is styled, Matthews v. Compass Group Diversified Holdings, LLC, et. al, No. 25-cv-00981 (C.D. Cal.).

Primech Regains Compliance with Nasdaq's Minimum Bid Price Requirement — Neutral
PMEC GlobeNewsWire — May 14, 2025SINGAPORE, May 14, 2025 (GLOBE NEWSWIRE) -- Primech Holdings Limited ("Primech" or the "Company") (Nasdaq: PMEC), an established technology-driven facility services provider in the public and private sectors operating mainly in Singapore, today announced that it has received notice from the Nasdaq Stock Market ("Nasdaq") on May 13, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on The Nasdaq Capital Market.

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma — Neutral
ACLX Business Wire — May 14, 2025REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan.

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma — Neutral
SDGR Business Wire — May 14, 2025NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, taking place June 17 - 21, 2025, in Lugano, Switzerland. The Phase 1 study is designed to evaluate the safet.

UnitedHealth Stock Has Dropped 43%. These Analysts Are Finally Downgrading the Shares. — Negative
UNH Barrons — May 14, 2025After the health insurer pulled its outlook for the year, analysts rushed to cut their predictions on the stock.
